Please Wait
Applying Filters...
menu
    • menu
    FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

    Data Compilation
    #PharmaFlow

    Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

    Stock Recap
    #PipelineProspector

    Menu

    Vedolizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Labeler NDC Package Code Non Proprietary Name Start Marketing Date End Marketing Date Category Code Dosage Form (Strength)
    27/02/2026 Patheon
    U.S.A
    		 Patheon Italia S.p.A. 68225-240 Vedolizumab 2014-05-20 2026-12-31 DRUG FOR FURTHER PROCESSING INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (300mg/5mL)
    27/02/2026 Takeda Pharmaceutical
    Japan
    		 Takeda Pharmaceutical Company Limited 11532-3002 VEDOLIZUMAB 2014-05-20 2026-12-31 DRUG FOR FURTHER PROCESSING INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (300mg/1)
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.